Nykredit A S Invests $140.59 Million in Gilead Sciences, Inc. $GILD

Key Points

• Nykredit A/S acquired 1.11 million Gilead shares worth approximately $140.6 million, representing 0.09% of the company. Institutional investors collectively own 83.67% of Gilead’s stock.
• Gilead expanded licensing agreements for its investigational once-yearly lenacapavir HIV-prevention formulation to 120 high-incidence countries and reached a separate agreement covering 14 Latin American and Caribbean countries, potentially broadening future market access.
• Gilead shares recently traded at $150.89, while analysts maintain a “Moderate Buy” consensus with an average price target of $158.78. The company reported 10.6% year-over-year revenue growth and declared a quarterly dividend of $0.82 per share.

Nykredit A S acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,112,764 shares of the biopharmaceutical company's stock, valued at approximately $140,587,000. Nykredit A S owned 0.09% of Gilead Sciences as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. BlackRock Inc. bought a new position in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $2,617,152,000. Legal & General Group Plc bought a new position in Gilead Sciences during the second quarter valued at about $1,316,606,000. Deutsche Bank AG acquired a new position in Gilead Sciences during the second quarter worth about $918,387,000. Finally, Boston Partners acquired a new position in Gilead Sciences during the fourth quarter worth about $517,808,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead expanded six royalty-free voluntary licensing agreements to include its investigational once-yearly lenacapavir formulation for HIV prevention. The agreements cover 120 high-incidence countries and support technology transfer, manufacturing readiness and future supply planning. The initiative could broaden the reach of Gilead’s HIV-prevention franchise, although the formulation remains investigational. Gilead global access planning article
• Positive Sentiment: A new agreement with the Pan American Health Organization could expand access to twice-yearly lenacapavir for HIV prevention in 14 Latin American and Caribbean countries. The deal strengthens the drug’s potential market reach and was welcomed by AIDS Healthcare Foundation, though it is primarily a long-term access and demand catalyst rather than an immediate earnings driver. PAHO-Gilead HIV prevention deal article
• Neutral Sentiment: Investors have shown heightened interest in Gilead, according to Zacks, but the report provided no new earnings estimate, rating change or company-specific catalyst. Gilead’s existing fundamentals include recent revenue growth and a quarterly dividend of $0.82 per share. Zacks investor interest article
• Negative Sentiment: CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 Gilead shares, worth approximately $435,870 and $432,660, respectively. Both transactions were executed under pre-arranged Rule 10b5-1 plans, and each executive retained a substantial stake, reducing the significance of the insider selling signal. Gilead insider selling article

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Barclays dropped their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 29th. Zacks Research raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 31st. Truist Financial dropped their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a report on Tuesday, July 7th. HSBC increased their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Finally, Weiss Ratings upgraded shares of Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $158.78.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares of the company's stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the transaction, the chief executive officer directly owned 577,133 shares of the company's stock, valued at $85,785,049.12. This represents a 2.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock valued at $14,616,390 over the last 90 days. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 2.2%

Shares of NASDAQ GILD opened at $150.89 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The company has a market cap of $187.10 billion, a price-to-earnings ratio of -56.51 and a beta of 0.33. The business has a fifty day simple moving average of $139.58 and a 200-day simple moving average of $136.22.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences's revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $2.01 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.